Dr. Sainath Bhethanabhotla-Medical Oncologist

Dr. Sainath Bhethanabhotla

MBBS, MD, DM (Medical Oncology)

Medical Oncologist

Practice Locations of Dr. Sainath Bhethanabhotla

Survey No.74, Financial District,

Nanakramguda, Hyderabad

Get Directions
OP Timings

Mon - Sat

09:30 am - 02:00 pm

Fee: 750

8-2-596/5, Rd No. 10, Gaffar Khan Colony,

Banjara Hills, Hyderabad

Get Directions
OP Timings

Mon, Wed, Fri

03:00 pm - 05:00 pm

Fee: 900

  • Practice Locations (2)

  • Profile

  • Patient Reviews

  • Q&A

Specializations

  • Medical Oncologist

  • Oncologist

Qualifications

  • MBBS - Osmania Medical College
  • MD - Internal Medicine - All India Institute Of Medical Sciences - New Delhi
  • DM - Medical Oncology - All India Institute Of Medical Sciences - New Delhi

Experiences

  • Senior Resident - Medical Oncology AIIMS - New Delhi
  • Resident Super Specialist MNJ Institute of Oncology and Regional Cancer Center - Hyderabad
  • Consultant Medical Oncologist Krishna Institute of Medical Sciences
  • Consultant Medical Oncologist American Oncology Institute - Hyderabad
  • Consultant Medical Oncologist Star Hospitals - Nanakramguda - Currently Working
  • Consultant Medical Oncologist Star Hospital - Banjara Hills - Currently Working

Awards and Recognitions

  • Abstract Achievement Award at American Society of Hematology Meeting on Hematological Malignancies held in Chicago for the abstract Prognostic Significance of Neutrophil - Lymphocyte Ratio in Advanced Pediatric Hodgkin Lymphoma - A Multicentric Analysis of 186 patients - 2016
  • Won Sorel Catherine Prize for Best Post Graduate in Pediatrics for the Year 2012
  • Stood 2nd in NNF Gold Medal Paper for the Year 2012(1)

Paper Presentations

  • Bhethanabhotla S, Bakhshi S, Reply : Neither Post - Treatment PET-CT Nor Interim PET - CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma, J Nucl Med. 2016 Dec8; IMPACT FACTOR: 7.439
  • Bhethanabhotla S, Jain S, Kapoor G, Mahajan A, Chopra A, Vishnubhatla S, Et Al. Outcome of Pediatric Advanced Hodgkin Lymphoma Treated with ABVD and Predictors of Inferior Survival : A Multicenter Study of 186 Patients, Leuk Lymphoma, 2016 Dec 6;1–7, IMPACT FACTOR:2.644
  • Bakhshi S, Bhethanabhotla S, Kumar R, Agarwal K, Sharma P, Thulkar S, Et Al, Post - Treatment PET - CT Rather Than Interim PET - CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma : A Prospective Study Comparing PET - CT Versus Conventional Imaging, J Nucl Med. 2016 Oct 6; IMPACT FACTOR: 7.439
  • Bhethanabhotla S, Bakhshi S, Presence of Risk Factors Does Not Affect Outcome in Early Stage Pediatric Hodgkin Lymphoma Treated with ABVD. Ann Hematol. 2016 Nov 18; Impact Factor : 2.845
  • Taywade SK, Kumar R, Bhethanabhotla S, Bal C. Role of (18) F -FDG PET - CT in Monitoring the Cyclophosphamide Induced Pulmonary Toxicity in Patients with Breast Cancer - 2 Case Reports, Nucl Med Mol Imaging, 2016 Sep;50(3):261–5
  • Kakkar A, Rajeshwari M, Bhethanabhotla S, Kaur K, Jain D, Gogia A, Et Al. Primary Diffuse Large B - Cell Lymphoma of the Prostate: A Report of Two Cases with Diagnostic Considerations, J Cancer Res Ther. 2015 Dec;11(4):977–9, Impact Factor: 0.8459
  • Gajendra S, Gogia A, Tanwar P, Sahoo MK, Bhethanabhotla S, Durgapal P, Et Al. Synchronous Metastatic Pulmonary Adenocarcinoma with Small Cell Lymphoma. Leuk Lymphoma. 2014 Jul;55(7):1678–80. IMPACT FACTOR: 2.644
  • Bhethanabhotla S, Thukral A, Sankar MJ, Agarwal R, Paul VK, Deorari AK. Effect of Position of Infant During Phototherapy in Management of Hyperbilirubinemia in Late Preterm and Term Neonates: A Randomized Controlled Trial. J Perinatol. 2013 Oct;33(10):795–9. IMPACT FACTOR: 2.183
  • Kumar L, Boya RR, Pai R, Harish P, Mookerjee A, Sainath B, Et Al. Autologous Stem Cell Transplantation for Multiple Myeloma: Long-Term Results. The National Medical Journal of India. 2016 Jul 1;29(4):192. IMPACT FACTOR: 0.786
  • Bhethanabhotla, S., Tiwari, A., Sharma, M.C. Et Al. Prognostic Significance of IL-6 In Hodgkin Lymphoma. Indian J Pediatr. 2019 Mar 4;Online First. IMPACT FACTOR: 1.046
  • Patel A, Tannock I, Bhethanabhola S, Srivastva P, Biswas B, Et Al. Low-Dose Abiraterone in Metastatic Prostate Cancer: Is it Practice Changing Facts and Facets.JCO Glob Oncol. 2020 Mar;6:382-386. IMPACT FACTOR:1.79

Report an error

Patient Reviews for Dr. Sainath Bhethanabhotla

No feedback

No feedback available for this Doctor.
Be the first to write a review.

Question & Answers by Dr. Sainath Bhethanabhotla

No Questions

No Question & Answers by this doctor.